Professional Documents
Culture Documents
Wounds Home
Supplements:
Current Issue Extracellular Wound Matrices:
Small Intestinal Submucosa Wound Matrix for Contem
Archives Issues
Chronic Wound Healing Wound
Search Articles - Jason P. Hodde, MS, ATC/L and Reynald Allam, MD, MBA Infectio
Manag
Subscribe to Wounds Risks,
Abstract: Chronic wounds represent a state where healing Treatin
Industry News Problem
has stagnated. Venous, diabetic, and pressure ulcers are
New Products typically difficult to heal and are at high risk of becoming Consen
chronic. In an attempt to restart the healing of chronic Statem
Classifieds Negativ
wounds, many biologically important molecules, such as Pressu
Continuing Education collagen, hyaluronic acid, and growth factors have been Wound
used to treat these wounds with varying degrees of success. Therap
Supplements the
Until recently, the idea of replacing the failing extracellular Manage
Enewsletters matrix (ECM) with an intact and biologically complex of Diab
substitute was unknown. Small Intestinal Submucosa Wound
Editorial Board
Wound Matrix (SISWM) is both a biologically complex and
Supple
Contact Us intact ECM, and an effective therapy for treating chronic
wounds. A drop in replacement for the ECM of difficult to
Author Instructions
heal or chronic wounds helps to stimulate tissue ingrowth, Special Publication:
Rapid Review deposition of new matrix, and rapid epithelialization The following is a collection of
publications from Healthpoint inten
potentially leading to improved quality of life for patients. facilitate expeditious, cost-effective
About Us
wound care management. There w
nine publications total.
Bioengineered skin equivalent Disclosure: This work was supported by Cook Biotech Newly
Funded
Incorporated. Dr. Allam is a paid consultant for Healthpoint, Selectiv
Negative pressure wound
therapy Ltd. Non-Se
Debride
Acellular dermal matrix CPT Co
The native dermis is normally able to direct wound Impact
Diabetic neuropathy
healing following damage but in chronic wounds, the dermal Hospita
Silver dressings extracellular matrix (ECM) and cells within it are diseased Owned
Enzymatic debridement Outpati
and unable to provide the correct signals needed to Wound
stimulate and coordinate healing.1,2 In deep, chronic Departm
Keywords: diabetic foot ulcers, pressure ulcers, or venous leg ulcers,
Novem
the dermal ECM may be completely absent and wounds may Clinical
Autolytic debridement
not efficiently epithelialize because the wound healing Experie
Wound necrosis signals that are usually present in the dermis have been with Oa
Surgical debridement Wound
lost. Functional ECM is essential to wound healing. The for the
Mechanical debridement healing process is stalled if functional ECM is absent in Treatm
Wound fibroblasts chronic wounds. In these particular situations, therapeutic Venous
Diabeti
Delayed wound healing strategies must include the use of exogenous factors to act Ulcers:
Impaired wound healing
as a surrogate for the native dermis if healing is expected to Series
occur. Cases
Compression stockings
View Al
Diabetic foot wounds
Pressure dressing
The Chronic Wound Problem
http://www.woundsresearch.com/article/7375 9/18/2007
Small Intestinal Submucosa Wound Matrix for Chronic Wound Healing -Wounds Page 2 of 8
The Buck Stops Here
65 years and older, venous leg ulcers affect approximately
Association of Advanced Wo
1.69%3 of the population in the United States and cost Care
approximately $9,600 to treat.4 In addition to the economic
Ostomy/Wound Manageme
costs, most patients with chronic venous leg ulcers report
pain (81%), itching (69%), and loss of sleep (67%) as a Podiatry Today
result of their wounds,5 as well as a significantly lower Vascular Disease Managem
quality of life.6 Of the 13.8 million people in the United Wound Healing Society
States diagnosed with diabetes,7 6% may develop foot
ulcers over a 3-year period8 with an estimated annual cost
of approximately $6 billion.9 More than 50% of people with Article Submission:
diabetes and a foot ulcer are expected to develop a wound All submissions for
infection, and up to 20% will require some degree of consideration should be
amputation during the course of their disease.10 Pressure submitted online using th
ulcers afflict approximately 15% of patients in acute care Rapid Review Web-Based
facilities11 and up to 29% in long-term care facilities,12 Review System at
www.rapidreview.com.
burdening the healthcare system with more than $8.5 billion
Authors should scroll dow
in annual costs.13 Pressure ulcers are often associated with HMP Communications an
fatal septic infections and are reported to cause thousands click on Author.
of deaths each year in the United States.14
Observed together, these data indicate that chronic
wounds are prevalent, costly, and have a significant
negative impact on quality of life. Therefore, effective
treatment strategies for chronic wounds could provide
tremendous benefits to both patients and society as a
whole. Unfortunately, complete healing rates for diabetic
foot ulcers, venous leg ulcers, or pressure ulcers remain at
approximately 25% to 50% following up to 20 weeks of
treatment when standard wound care therapies and
traditional synthetic dressings are used.1517 These low
rates suggest that standard of care is inadequate for many
patients while highlighting the need for more aggressive
management strategies in this population. Significant cost
savings, decreased morbidity, and substantial increases in
quality of life can be achieved with more rapid and complete
ulcer healing.
http://www.woundsresearch.com/article/7375 9/18/2007
Small Intestinal Submucosa Wound Matrix for Chronic Wound Healing -Wounds Page 3 of 8
http://www.woundsresearch.com/article/7375 9/18/2007
Small Intestinal Submucosa Wound Matrix for Chronic Wound Healing -Wounds Page 4 of 8
Clinical Applications
http://www.woundsresearch.com/article/7375 9/18/2007
Small Intestinal Submucosa Wound Matrix for Chronic Wound Healing -Wounds Page 5 of 8
Summary
http://www.woundsresearch.com/article/7375 9/18/2007
Small Intestinal Submucosa Wound Matrix for Chronic Wound Healing -Wounds Page 6 of 8
References
http://www.woundsresearch.com/article/7375 9/18/2007
Small Intestinal Submucosa Wound Matrix for Chronic Wound Healing -Wounds Page 7 of 8
(1):17.
5. Hareendran A, Bradbury A, Budd J, et al. Measuring the impact
of venous leg ulcers on quality of life. J Wound Care. 2005;14
(2):5357.
6. Nabuurs-Franssen MH, Huijberts MS, Nieuwenhuijzen
Kruseman AC, Willems J, Schaper NC. Health-related quality of
life of diabetic foot ulcer patients and their caregivers.
Diabetologia. 2005;48(9):19061910.
7. Centers for Disease Control and Prevention. National diabetes
surveillance system. Available at:
http://www.cdc.gov/diabetes/statistics/prev/national/figpersons.htm.
Accessed February 6, 2007.
8. Ramsey SD, Newton K, Blough D, et al. Incidence, outcomes,
and cost of foot ulcers in patients with diabetes. Diabetes Care.
1999;22(3):382387.
9. Gordois A, Scuffham P, Shearer A, Oglesby A, Tobian JA. The
health care costs of diabetic peripheral neuropathy in the US.
Diabetes Care. 2003;26(6):17901795.
10. Wu S, Armstrong DG. Risk assessment of the diabetic foot and
wound. Int Wound J. 2005;2(1):1724.
11. Amlung SR, Miller WL, Bosley LM. The 1999 National Pressure
Ulcer Prevalence Survey: a benchmarking approach. Adv Skin
Wound Care. 2001;14(6):297301.
12. National Pressure Ulcer Advisory Panel. Pressure ulcers in
America: prevalence, incidence, and implications for the future. An
executive summary of the National Pressure Ulcer Advisory Panel
monograph. Adv Skin Wound Care. 2001;14(4):208215.
13. Beckrich K, Aronovitch SA. Hospital-acquired pressure ulcers:
a comparison of costs in medical vs. surgical patients. Nurs Econ.
1999;17(5):263271.
14. Redelings MD, Lee NE, Sorvillo F. Pressure ulcers: more lethal
than we thought? Adv Skin Wound Care. 2005;18(7):367372.
15. Margolis DJ, Allen-Taylor L, Hoffstad O, Berlin JA. Healing
diabetic neuropathic foot ulcers: are we getting better? Diabet
Med. 2005;22(2):172176.
16. Veves A, Sheehan P, Pham HT. A randomized, controlled trial
of Promogran (a collagen/oxidized regenerated cellulose dressing)
vs standard treatment in the management of diabetic foot ulcers.
Arch Surg. 2002;137(7):822827.
17. Franks PJ, Moffatt CJ. Health related quality of life in patients
with venous ulceration: use of the Nottingham health profile. Qual
Life Res. 2001;10(8):693700.
18. Niezgoda JA, Van Gils CC, Frykberg RG, Hodde JP.
Randomized clinical trial comparing OASIS Wound Matrix to
Regranex Gel for diabetic ulcers. Adv Skin Wound Care. 2005;18
(5 Pt 1):258266.
19. Demling RH, Niezgoda JA, Haraway GD, Mostow EN. Small
intestinal submucosa wound matrix and full-thickness venous
ulcers: preliminary results. WOUNDS. 2004;16(1):1822.
20. Mostow EN, Haraway GD, Dalsing M, Hodde JP, King D;
OASIS Venous Ulcer Study Group. Effectiveness of an
extracellular matrix graft (Oasis Wound Matrix) in the treatment of
chronic leg ulcers: a randomized clinical trial. J Vasc Surg. 2005;41
(5):837843.
21. Vazquez JR, Short B, Findlow AH, Nixon BP, Boulton AJ,
Armstrong DG. Outcomes of hyaluronan therapy in diabetic foot
wounds. Diabetes Res Clin Pract. 2003;59(2):123127.
22. Wieman TJ, Smiell JM, Su Y. Efficacy and safety of a topical
gel formulation of recombinant human platelet-derived growth
factor-BB (becaplermin) in patients with chronic neuropathic
diabetic ulcers. A phase III randomized placebo-controlled double-
blind study. Diabetes Care. 1998;21(5):822827.
23. Margolis DJ, Kantor J, Berlin JA. Healing of diabetic
neuropathic foot ulcers receiving standard treatment. A meta-
analysis. Diabetes Care. 1999;22(5):692695.
24. Solomon DE. An in vitro examination of an extracellular matrix
scaffold for use in wound healing. Int J Exp Pathol. 2002;83
(5):209216.
25. Hodde, J. Naturally-occurring scaffolds for soft tissue repair
and regeneration. Tissue Eng. 2002;8(2):295308.
26. Badylak SF. Small intestinal submucosa (SIS): a biomaterial
conducive to smart tissue remodeling. In: Bell E, ed. Tissue
Engineering: Current Perspectives. Cambridge, Mass: Burkhauser
Publishers; 1993:179189.
27. Hodde JP, Hiles MC. Virus safety of a porcine-derived medical
device: evaluation of a viral inactivation method. Biotechnol
http://www.woundsresearch.com/article/7375 9/18/2007
Small Intestinal Submucosa Wound Matrix for Chronic Wound Healing -Wounds Page 8 of 8
Bioeng. 2002;79(2):211216.
28. Kropp BP, Rippy MK, Badylak SF, et al. Regenerative urinary
bladder augmentation using small intestinal submucosa:
urodynamic and histopathologic assessment in long term canine
bladder augmentations. J Urol. 1996;155(6):20982104.
29. Sandusky GE Jr, Badylak SF, Morff RJ, Johnson WD, Lantz G.
Histologic findings after in vivo placement of small intestinal
submucosal vascular grafts and saphenous vein grafts in the
carotid artery in dogs. Am J Pathol. 1992;140(2):317324.
30. McPherson TB, Badylak SF. Characterization of fibronectin
derived from porcine small intestinal submucosa. Tissue Eng.
1998;4(1):7583.
31. Hodde JP, Badylak SF, Brightman AO, Voytik-Harbin SL.
Glycosaminoglycan content of small intestinal submucosa: a
bioscaffold for tissue replacement. Tissue Eng. 1996;2(3):209
217.
32. Hodde JP, Ernst DM, Hiles MC. An investigation of the long-
term bioactivity of endogenous growth factor in Oasis Wound
Matrix. J Wound Care. 2005;14(1):2325.
33. McDevitt CA, Wildey GM, Cutrone RM. Transforming growth
factor-b1 in a sterilized tissue derived from the pig small intestine
submucosa. J Biomed Mater Res. 2003;67(2):637640.
34. Harrington C, Zagari MJ, Corea J, Klitenic J. A cost analysis of
diabetic lower-extremity ulcers. Diabetes Care. 2000;23(9):1333
1338.
35. Xue M, Le NT, Jackson CJ. Targeting matrix metalloproteases
to improve cutaneous wound healing. Expert Opin Ther Targets.
2006;10(1):143155.
36. Quatresooz P, Henry F, Paquet P, Pierard-Franchimont C,
Harding K, Pierard GE. Deciphering the impaired cytokine
cascades in chronic leg ulcers (review). Int J Mol Med. 2003;11
(4):411418.
37. MacNeil S. What role does the extracellular matrix serve in skin
grafting and wound healing? Burns. 1994;20(Suppl 1):S67S70.
38. Hodde JP, Hiles MC. Bioactive FGF-2 in sterilized extracellular
matrix. WOUNDS. 2001;13(5):195201.
39. Sheehan P, Jones P, Caselli A, Giurini JM, Veves A. Percent
change in wound area of diabetic foot ulcers over a 4-week period
is a robust predictor of complete healing in a 12-week prospective
trial. Diabetes Care. 2003;26(6):18791882.
40. Kantor J, Margolis DJ. A multicentre study of percentage
change in venous leg ulcer area as a prognostic index of healing at
24 weeks. Br J Dermatol. 2000;142(5):960964.
41. Boulton AJ, Kirsner RS, Vileikyte L. Clinical practice.
Neuropathic diabetic foot ulcers. N Engl J Med. 2004;351(1):48
55.
Wounds - ISSN: 1044-7946 - Volume 19 - Issue 6 - June
2007 - Pages: 157 - 162
http://www.woundsresearch.com/article/7375 9/18/2007